TY - JOUR
T1 - Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease
T2 - Current Perspectives
AU - Zulfikar, Sabrina
AU - Mulholland, Sarah
AU - Adamali, Huzaifa
AU - Barratt, Shaney L
N1 - © 2020 Zulfikar et al.
PY - 2020
Y1 - 2020
N2 - Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.
AB - Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.
U2 - 10.2147/CPAA.S228362
DO - 10.2147/CPAA.S228362
M3 - Review article (Academic Journal)
C2 - 32765123
VL - 12
SP - 97
EP - 108
JO - Clinical pharmacology : advances and applications
JF - Clinical pharmacology : advances and applications
SN - 1179-1438
ER -